Effectiveness of Erythropoiesis-Stimulating Agent Therapy With Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients. JFM 2026, 9 (1), 499-507. https://doi.org/10.35451/jfm.v9i1.3691.